These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8799087)

  • 1. Cost-effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia.
    Salkeld G; Young G; Irwig L; Haas M; Glasziou P
    Aust N Z J Public Health; 1996 Apr; 20(2):138-43. PubMed ID: 8799087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of colonoscopy in screening for colorectal cancer.
    Sonnenberg A; Delcò F; Inadomi JM
    Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation.
    Daniels K; McKee M
    J R Army Med Corps; 1995 Oct; 141(3):142-50. PubMed ID: 8568748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of screening for colorectal cancer in the general population.
    Frazier AL; Colditz GA; Fuchs CS; Kuntz KM
    JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy.
    O'Leary BA; Olynyk JK; Neville AM; Platell CF
    J Gastroenterol Hepatol; 2004 Jan; 19(1):38-47. PubMed ID: 14675241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for colorectal cancer using the faecal occult blood test, hemoccult.
    Towler BP; Irwig L; Glasziou P; Weller D; Kewenter J
    Cochrane Database Syst Rev; 2000; (2):CD001216. PubMed ID: 10796760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
    Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K
    Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal cancer screening in Australia: an economic evaluation of a potential biennial screening program using faecal occult blood tests.
    Stone CA; Carter RC; Vos T; John JS
    Aust N Z J Public Health; 2004 Jun; 28(3):273-82. PubMed ID: 15707175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
    Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
    Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K
    Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
    Tsoi KK; Ng SS; Leung MC; Sung JJ
    Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
    Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential benefits and harms of screening for colorectal cancer.
    Towler B; Irwig L; Glasziou P; Haas M; Plunkett A; Salkeld G
    Aust J Public Health; 1995 Feb; 19(1):24-8. PubMed ID: 7734588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colorectal cancer screening in Italy: feasibility and cost-effectiveness in a model area.
    Sorrentino D; Paduano R; Bernardis V; Piccolo A; Bartoli E
    Eur J Gastroenterol Hepatol; 1999 Jun; 11(6):655-60. PubMed ID: 10418938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries.
    Wu GH; Wang YM; Yen AM; Wong JM; Lai HC; Warwick J; Chen TH
    BMC Cancer; 2006 May; 6():136. PubMed ID: 16723013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimates of costs and effects of screening for colorectal cancer in the United States.
    Byers T; Gorsky R
    Cancer; 1992 Sep; 70(5 Suppl):1288-95. PubMed ID: 1387342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of screening for colorectal cancer: evidence from the Nottingham faecal occult blood trial.
    Whynes DK;
    J Med Screen; 2004; 11(1):11-5. PubMed ID: 15006108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
    Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
    Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.